Disease-Modifying Antirheumatic Drug (DMARD) Market, by Drug Type (Synthetic (sDMARD), (Conventional synthetic (csDMARDs), (Methotrexate, Sulfasalazine, Leflunomide, Hydroxychloroquine and Gold Salts), Targeted synthetic DMARDs (tsDMARDs), Biological DMARDs (bDMARD), (Original DMARDs (boDMARDs), Biosimilar DMARDs (bsDMARDs), (Primary, Secondary and Tertiary) and Others), by Route of Administration (Oral, Parenteral and Others), by Indication (Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Systemic Lupus Erythematosus and Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia-Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030
Disease-modifying anti-rheumatic drugs (DMARDs) can treat the underlying cause of condition and reduce inflammation. They are given to people with autoimmune conditions, such as rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, ankylosing spondylitis and others. These are conditions where the immune system, which normally fights infection, attacks the body’s own healthy tissues. DMARDs can improve symptoms such as pain, stiffness and swelling, but they may take a few weeks or even months to fully take effect. There are different types of DMARDs, and they work in slightly different ways. The three main types are: synthetic (sDMARD), targeted synthetic DMARDs, biological DMARDs (bDMARD) and others
Market Dynamics
Key players operating in the global disease-modifying anti-rheumatic drugs (DMARDs) market are focusing on increasing product launches and product approvals which is expected to drive the market growth during the forecast period. For instance, in January 2018, Hetero, one of the leading generic pharmaceutical companies launched its fourth biosimilar drug ‘Adalimumab’ under the brand name ‘Mabura’ in India. Mabura is an anti-inflammatory biologic medication specific for human tumor necrosis factor (TNF). It is indicated for the treatment of rheumatoid arthritis and other auto-immune disorders such as psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, and ulcerative colitis. Moreover, in September 2020, Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation announced that the U.S. Food and Drug Administration (FDA) approved XELJANZ (tofacitinib) for the treatment of children and adolescents 2 years and older with active polyarticular course juvenile idiopathic arthritis (pcJIA). Two formulations were approved, a tablet and an oral solution, and are dosed based upon weight. This approval makes XELJANZ the first and only Janus kinase (JAK) inhibitor approved in the U.S. for the treatment of pcJIA.
Key features of the study:
- This report provides an in-depth analysis of the global disease-modifying anti-rheumatic drugs (DMARDs) market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global disease-modifying anti-rheumatic drugs (DMARDs) market based on the following parameters – Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
- Key companies covered as a part of this study include Sanofi., Pfizer, F. Hoffman-La Roche AG, Johnson & Johnson, AbbVie Inc., Eli Lilly & Company, Amgen Inc., Swedish Orphan Biovitrum AB, Bristol-Myers Squibb Company, UCB S.A., Gilead Sciences, Inc., and Cumberland Pharmaceuticals Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global disease-modifying anti-rheumatic drugs (DMARDs) market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global disease-modifying anti-rheumatic drugs (DMARDs) market
- Global Disease-Modifying Anti-Rheumatic Drugs (DMARDs) Market, By Drug Type:
- Synthetic (sDMARD)
- Conventional synthetic (csDMARDs)
- Methotrexate
- Sulfasalazine
- Leflunomide
- Hydroxychloroquine
- Gold Salts
- Targeted synthetic DMARDs (tsDMARDs)
- Biological DMARDs (bDMARD)
- Original DMARDs (boDMARDs)
- Biosimilar DMARDs (bsDMARDs)
- Primary
- Secondary
- Tertiary
- Others
- Global Disease-Modifying Anti-Rheumatic Drugs (DMARDs) Market, By Route of Administration :
- Oral
- Parenteral
- Others
- Global Disease-Modifying Anti-Rheumatic Drugs (DMARDs) Market, By Indication :
- Rheumatoid Arthritis
- Ankylosing Spondylitis
- Psoriatic Arthritis
- Systemic Lupus Erythematosus
- Others
- Global Disease-Modifying Anti-Rheumatic Drugs (DMARDs) Market, By Distribution Channel :
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Global Disease-Modifying Anti-Rheumatic Drugs (DMARDs) Market, By Region:
- North America
- By Country
- U.S.
- Canada
- Latin America
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Country
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Sanofi *
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Pfizer.
- F. Hoffman-La Roche AG
- Johnson & Johnson
- AbbVie Inc.
- Eli Lilly & Company
- Amgen Inc.
- Swedish Orphan Biovitrum AB
- Bristol-Myers Squibb Company
- UCB S.A.
- Gilead Sciences, Inc.
- Cumberland Pharmaceuticals Inc.
- 1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- 2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Route of Drug Administration
- Market Snapshot, By Indication
- Market Snapshot, By Distribution Channels
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
- 3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunity
- Impact Analysis
- Regulatory Scenario
- Market Trends
- Key Developments
- Epidemiology
- PEST Analysis
- Collaboration and Acquisition
- Porters Analysis
- Pipeline Analysis
- 4. Global Disease-Modifying Antirheumatic Drug (DMARD) Market– Impact of Coronavirus (COVID-19) Pandemic
- Economic Impact
- Impact on Demand and Supply
- COVID-19 Impact Assessments
- 5. Global Disease-Modifying Antirheumatic Drug (DMARD) Market, By Drug Type, 2017-2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- Synthetic (sDMARD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
- Conventional synthetic (csDMARDs)
- Methotrexate
- Sulfasalazine
- Leflunomide
- Hydroxychloroquine
- Gold Salts
- Targeted synthetic DMARDs (tsDMARDs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
- Biological DMARDs (bDMARD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
- Original DMARDs (boDMARDs)
- Biosimilar DMARDs (bsDMARDs)
- Primary
- Secondary
- Tertiary
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
- 6. Global Disease-Modifying Antirheumatic Drug (DMARD) Market, By Route of Drug Administration, 2017-2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
- 7. Global Disease-Modifying Antirheumatic Drug (DMARD) Market, By Indication, 2017-2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- Rheumatoid Arthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
- Ankylosing Spondylitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
- Psoriatic Arthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
- Systemic Lupus Erythematosus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
- 8. Global Disease-Modifying Antirheumatic Drug (DMARD) Market, By Distribution Channel, 2017-2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- Hospital Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
- Retail Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
- Online Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
- 9. Global Disease-Modifying Antirheumatic Drug (DMARD) Market, By Region, 2017-2030, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017–2030
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Drug Administration, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Drug Administration, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Drug Administration, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
- U.K.
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Drug Administration, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Drug Administration, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Drug Administration, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017-2030,(US$ Mn)
- North Africa
- Central Africa
- South Africa
- 10. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Sanofi.*
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Pfizer
- Hoffman-La Roche AG
- Johnson & Johnson
- AbbVie Inc.
- Eli Lilly & Company
- Amgen Inc.
- Swedish Orphan Biovitrum AB
- Bristol-Myers Squibb Company
- UCB S.A.
- Gilead Sciences, Inc.
- Cumberland Pharmaceuticals Inc.
- 11. Section
- Research Methodology
- About us
- *Browse 27 market data tables and 31 figures on "Global Disease-Modifying Antirheumatic Drug (DMARD) Market” - Forecast to 2030
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook